Travere Therapeutics (TVTX) announced that the FDA granted full approval to its oral nonimmunosuppressive drug Filspari (sparsentan) in IgA nephropathy (IgAN) indication, a rare progressive kidney disease. Following this decision, Filspari is approved for slowing kidney function decline in adults with primary IgAN who are at risk of disease progression. The FDA's decision also makes Filspari the only nonimmunosuppressive medication in the IgAN space. Filspari was initially granted accelerated approval in Fe ...